Haemonetics
This article was originally published in The Gray Sheet
Executive Summary
Maker of automated blood processing systems says it will acquire the remaining 80% of Transfusion Technologies Corp. not already owned. The cash deal was announced Sept. 5. Haemonetics will gain Tranfusion Technologies' orthopedic perioperative autotransfusion system OrthoPat, which incorporates Dynamic Disc centrifuge technology, as well as access to the Chairside Separator, an automated whole blood collection device in late-stage development. The Dynamic Disk centrifuge system "has tremendous synergy with Haemonetics' core product line and a very promising marketing potential," the firm says. Last November, Haemonetics bought about 20% of TTC for $15 mil
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.